MA34487B1 - Compositions d'anticorps anti-vegfr-3. - Google Patents

Compositions d'anticorps anti-vegfr-3.

Info

Publication number
MA34487B1
MA34487B1 MA35695A MA35695A MA34487B1 MA 34487 B1 MA34487 B1 MA 34487B1 MA 35695 A MA35695 A MA 35695A MA 35695 A MA35695 A MA 35695A MA 34487 B1 MA34487 B1 MA 34487B1
Authority
MA
Morocco
Prior art keywords
vegfr
antibody compositions
antibodies
treat
disease
Prior art date
Application number
MA35695A
Other languages
English (en)
French (fr)
Inventor
Bronislaw Pytowski
Krishnadatt Persaud
Nathalie Zayek
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34487(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MA34487B1 publication Critical patent/MA34487B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA35695A 2010-09-07 2011-09-01 Compositions d'anticorps anti-vegfr-3. MA34487B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (1)

Publication Number Publication Date
MA34487B1 true MA34487B1 (fr) 2013-08-01

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35695A MA34487B1 (fr) 2010-09-07 2011-09-01 Compositions d'anticorps anti-vegfr-3.

Country Status (26)

Country Link
US (2) US8481034B2 (enExample)
EP (1) EP2614081B1 (enExample)
JP (1) JP2013538813A (enExample)
KR (1) KR20130042601A (enExample)
CN (1) CN103080133A (enExample)
AR (1) AR082641A1 (enExample)
AU (1) AU2011299443B2 (enExample)
BR (1) BR112013005423A2 (enExample)
CA (1) CA2809375C (enExample)
CL (1) CL2013000607A1 (enExample)
CO (1) CO6690754A2 (enExample)
CR (1) CR20130065A (enExample)
DO (1) DOP2013000039A (enExample)
EA (1) EA023331B1 (enExample)
EC (1) ECSP13012481A (enExample)
ES (1) ES2568801T3 (enExample)
GT (1) GT201300058A (enExample)
MA (1) MA34487B1 (enExample)
MX (1) MX2013002718A (enExample)
PE (1) PE20131328A1 (enExample)
PH (1) PH12013500432A1 (enExample)
SG (1) SG188265A1 (enExample)
TW (1) TWI413527B (enExample)
UA (1) UA109148C2 (enExample)
WO (1) WO2012033696A1 (enExample)
ZA (1) ZA201300804B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
CN107405410B (zh) * 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체

Also Published As

Publication number Publication date
PH12013500432A1 (en) 2017-08-23
EA023331B1 (ru) 2016-05-31
EP2614081A1 (en) 2013-07-17
MX2013002718A (es) 2013-05-01
WO2012033696A1 (en) 2012-03-15
TWI413527B (zh) 2013-11-01
PE20131328A1 (es) 2013-11-18
DOP2013000039A (es) 2013-04-15
EP2614081B1 (en) 2016-03-16
ES2568801T3 (es) 2016-05-04
CO6690754A2 (es) 2013-06-17
EA201390117A1 (ru) 2013-06-28
KR20130042601A (ko) 2013-04-26
ZA201300804B (en) 2014-07-30
ECSP13012481A (es) 2015-03-31
US8784818B2 (en) 2014-07-22
US20120058126A1 (en) 2012-03-08
JP2013538813A (ja) 2013-10-17
CN103080133A (zh) 2013-05-01
GT201300058A (es) 2014-07-16
UA109148C2 (uk) 2015-07-27
AR082641A1 (es) 2012-12-19
US8481034B2 (en) 2013-07-09
US20130280278A1 (en) 2013-10-24
CL2013000607A1 (es) 2014-04-11
AU2011299443A1 (en) 2013-02-14
CA2809375C (en) 2016-02-09
CA2809375A1 (en) 2012-03-15
SG188265A1 (en) 2013-04-30
CR20130065A (es) 2013-03-21
AU2011299443B2 (en) 2014-06-05
BR112013005423A2 (pt) 2016-06-07
TW201223543A (en) 2012-06-16

Similar Documents

Publication Publication Date Title
MA35433B1 (fr) Anticorps anti-pcsk9 et leurs utilisations
MA31984B1 (fr) Formulation d'anticorps
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA32894B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide
MA38161A1 (fr) Anticorps anti-bmp-6
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA35724B1 (fr) Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
NZ599628A (en) Axl antibodies
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
UA92505C2 (ru) Композиции на основе антитела против cd3
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
MA34763B1 (fr) Anticorps anti-cd38
MA30382B1 (fr) Anticorps monoclonaux humanises contre le facteur de croissance des hepatocytes
MA33052B1 (fr) Variants de liaison anti-albumine sérique améliorés
MA38396A1 (fr) Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
MA32895B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine